Comparison 3. Interleukin‐2 receptor antagonist versus no induction.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Acute rejection	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Pneumonia	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 CMV infection	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Bronchiolitis obliterans syndrome	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
5.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]